Health Affairs: Addressing Out-Of-Pocket Specialty Drug Costs In Medicare Part D: The Good, The Bad, The Ugly, And The Ignored

“Solving the problem of high out-of-pocket cost burden will require a multipronged approach. Even sizeable decreases in very high specialty drug list prices are unlikely to lead to major improvements in access without instituting an annual out-of-pocket maximum and paying significant attention to the timing and magnitude of out-of-pocket costs under the current Part D structure. Options are available to redistribute and alleviate current out-of-pocket cost burden without substantially increasing overall costs.” Read more at Health Affairs